Contact Lens Spectrum

References

July 2018

Document #272

(p. 11) Editor’s Perspective – Let the Sunshine In
By Jason J. Nichols, OD, MPH, PhD

  1. Jones RG, Ornstein C, Tigas M. We’ve Updated Dollars for Docs. Here’s What’s New. ProPublica. 2016 Dec 13. Available at https://www.propublica.org/article/updated-dollars-for-docs-heres-whats-new . Accessed on Jun. 18, 2018.

(p. 12) Research Review – Neuropathic Pain
By Maria Markoulli, PhD, MOptom, GradCertOcTher

  1. Galor A, Moein HR, Lee C, et al. Neuropathic pain and dry eye. The Ocular Surface. 2018 Jan;16:31-44.
  2. Galor A, Levitt RC, Felix ER, Sarantopoulos CD. Neuropathic ocular pain: an important yet underevaluated feature of dry eye. Eye (Lond). 2015 Mar;29:301-312.
  3. Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017 Jul;15:276-283.
  4. Belmonte C, Nichols JJ, Cox SM, et al. TFOS DEWS II pain and sensation report. Ocul Surf. 2017 Jul;15:404-437.
  5. Crane AM, Feuer W, Felix ER, et al. Evidence of central sensitisation in those with dry eye symptoms and neuropathic-like ocular pain complaints: incomplete response to topical anaesthesia and generalised heightened sensitivity to evoked pain. Br J Ophthalmol. 2017 Sep;101:1238-1243.
  6. Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000 May;118:615-621.
  7. Begley CG, Chalmers RL, Mitchell GL, et al. Characterization of ocular surface symptoms from optometric practices in North America. Cornea. 2001 Aug;20:610-618.
  8. Qazi Y, Hurwitz S, Khan S, Jurkunas UV, Dana R, Hamrah P. Validity and reliability of a novel Ocular Pain Assessment Survey (OPAS) in quantifying and monitoring corneal and ocular surface pain. Ophthalmology. 2016 Jul;123:1458-1468.
  9. Jacobs DS. Diagnosis and Treatment of Ocular Pain: the Ophthalmologist's Perspective. Curr Ophthalmol Rep. 2017;5(4):271-275.
  10. Galor A, Levitt RC, McManus KT, et al. Assessment of somatosensory function in patients with idiopathic dry eye symptoms. JAMA Ophthalmol. 2016 Nov;134,:1290-1298.
  11. Oliveira-Soto L, Efron N. Morphology of corneal nerves using confocal microscopy. Cornea. 2001 May;20:374-384.
  12. Belmonte C, Nichols JJ, Cox SM, et al. TFOS DEWS II pain and sensation report. Ocul Surf, 15, 404-437.
  13. Crane AM, Levitt RC, Felix ER, Sarantopoulos KD, McClellan AL, Galor A. Patients with more severe symptoms of neuropathic ocular pain report more frequent and severe chronic overlapping pain conditions and psychiatric disease. Br J Ophthalmol. 2017 Feb;101:227-231.
  14. Galor A, Covington D, Levitt AE, et al. Neuropathic ocular pain due to dry eye is associated with multiple comorbid chronic pain syndromes. J Pain. 2016 Mar;17:310-318.
  15. Ozen S, Ozer MA, Akdemir MO. Vitamin B12 deficiency evaluation and treatment in severe dry eye disease with neuropathic ocular pain. Graefes Arch Clin Exp Ophthalmol. 2017 Jun;255:1173-1177.
  16. Wiffen PJ, Derry S, Bell RF, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017 Jun 9;6:CD007938.
  17. Galor A, Batawi H, Felix ER, et al. Incomplete response to artificial tears is associated with features of neuropathic ocular pain. Br J Ophthalmol. 2016 Jun;100:745-749.

(p. 14) Prescribing for Presbyopia – Managing Dry Eye in Presbyopic Lens Wearers
By Thomas G. Quinn, OD, MS

  1. Moss SE, Klein R, Klein BE. Long-term incidence of dry eye in an older population. Optom Vis Sci. 2008 Aug;85:668-674.
  2. Simpson TL, Situ P, Jones LW, Fonn D. Dry eye symptoms assessed by four questionnaires. Optom Vis Sci. 2008 Aug;85:692-699.
  3. Wolffsohn JS, Arita R, Chalmers R, et al. TFOS DEWS II Diagnostic Methodology report. Ocul Surf. 2017 Jul;15:539-574.
  4. de la Jara PL, Papas E, Diec J, Naduvilath T, Willcox MD, Holden BA. Effect of lens care systems on the clinical performance of a contact lens. Optom Vis Sci. 2013 Apr;90:344-350.
  5. Lira M, Franco S, Vazquez-Dorrio JB, Real Oliveira ME, Costa MF. Surface roughness and refractive index changes in contact lens induced by lens care systems. Eye Contact Lens. 2014 May;40:140-147.

(p. 15) GP Insights – GP Lens-Induced Dryness Symptoms and Signs
By Edward S. Bennett, OD, MSEd; Melanie Frogozo, OD; Mile Brujic, OD; & Robert Grohe, OD

  1. Bennett ES, Sorbara L, Kojima R. Gas-permeable lens design, fitting and evaluation. In Bennett ES, Henry VA. Clinical Manual of Contact Lenses, 4th ed. Wolters Kluwer/Lippincott Williams & Wilkins, 2014:112-156.
  2. Safety Memos. Eye Safety-The 20/20/20 Rule-Computer Vision Syndrome. 2014 Jun 30. Available at https://www.youtube.com/watch?v=_7hwZv36JMU . Accessed on May 30, 2018.
  3. Moon JH, Kim KW, Moon NJ. Smartphone use is a risk factor for pediatric dry eye disease according to region and age: a case control study. BMC Ophthalmology 2016 Oct 28;16;188.

(p. 18) Dry Eye Dx and Tx – Diving into the 2018 Dry Eye Pipeline
By William Townsend, OD

  1. U.S. Food and Drug Administration. www.fda.gov
  2. Tsai PS, Evans JE, Green KM, et al. Proteomic analysis of human meibomian gland secretions. Br J Ophthalmol. 2006 Mar;90:372-377.
  3. Samudre S, Lattanzio FA, Lossen V, et al. Lacritin, a novel human tear glycoprotein, promotes sustained basal tearing and is well tolerated. Invest Ophthalmol Vis Sci. 2011 Aug 5;52:6265-6270.
  4. McNamara NA, Ge S, Lee SM, et al. Reduced Levels of Tear Lacritin Are Associated With Corneal Neuropathy in Patients With the Ocular Component of Sjögren's Syndrome. Invest Ophthalmol Vis Sci. 2016 Oct 1;57:5237-5243.
  5. TearSolutions Inc. Lacriprep™ in Subjects with Dry Eye Associated with Primary Sjögren’s Syndrome. Posted Jul. 21, 2017. Updated Apr. 20, 2018. Available at https://clinicaltrials.gov/ct2/show/study/NCT03226444 .
  6. DrugBank. Brimonidine. Available at https://www.drugbank.ca/drugs/DB00484 . Accessed on Jun 18, 2018.
  7. Ocugen. Pipeline Overview. Available at https://ocugen.com/pipeline/overview . Accessed on Jun 18, 2018.
  8. Zhang Y, Kam WR, Liu Y, Chen X, Sullivan DA. Influence of Pilocarpine and Timolol on Human Meibomian Gland Epithelial Cells. Cornea. 2017 Jun;36:719-724.
  9. Han X, Liu Y, Kam WR, Sullivan DA. Effect of brimonidine, an α2 adrenergic agonist, on human meibomian gland epithelial cells. Exp Eye Res. 2018 May;170:20-28.

(p. 19) Contact Lens Care & Compliance – Improving Lens Comfort with Orthokeratology
By Andrew D. Pucker, OD, PhD, & Kim Duong, OD, MS

  1. Pritchard N, Fonn D, Brazeau D. Discontinuation of contact lens wear: a survey. Int Contact Lens Clin. 1999 Nov;26:157-162.
  2. Dumbleton K, Woods CA, Jones LW, Fonn D. The impact of contemporary contact lenses on contact lens discontinuation. Eye Contact Lens. 2013 Jan;39:93-99.
  3. García-Porta N, Rico-Del-Viejo L, Martin-Gil A, Carracedo G, Pintor J, González-Méijome JM. Differences in Dry Eye Questionnaire Symptoms in Two Different Modalities of Contact Lens Wear: Silicone-Hydrogel in Daily Wear Basis and Overnight Orthokeratology. Biomed Res Int. 2016;2016:1242845.
  4. Chalmers RL, Begley CG. Dryness symptoms among an unselected clinical population with and without contact lens wear. Cont Lens Anterior Eye. 2006 Mar;29:25-30.
  5. Richdale K, Sinnott LT, Skadahl E, Nichols JJ. Frequency of and factors associated with contact lens dissatisfaction and discontinuation. Cornea. 2007 Feb;26:168-174.
  6. Dumbleton K, Caffery B, Dogru M, et al. The TFOS International Workshop on Contact Lens Discomfort: report of the subcommittee on epidemiology. Invest Ophthalmol Vis Sci. 2013 Oct;54:TFOS20-36.
  7. Nichols JJ, Willcox MD, Bron AJ, et al. The TFOS International Workshop on Contact Lens Discomfort: executive summary. Invest Ophthalmol Vis Sci. 2013 Oct;54:TFOS7-TFOS13.
  8. Begley CG, Chalmers RL, Mitchell GL, et al. Characterization of ocular surface symptoms from optometric practices in North America. Cornea. 2001 Aug;20:610-618.
  9. Caroline PJ. Contemporary orthokeratology. Cont Lens Anterior Eye. 2001;24(1):41-46.
  10. Dave T, Ruston D. Current trends in modern orthokeratology. Ophthalmic Physiol Opt. 1998 Mar;18:224-233.
  11. Lipson MJ, Sugar A, Musch DC. Overnight corneal reshaping versus soft disposable contact lenses: vision-related quality-of-life differences from a randomized clinical trial. Optom Vis Sci. 2005 Oct;82:886-891.
  12. Carracedo G, Martin-Gil A, Fonseca B, Pintor J. Effect of overnight orthokeratology on conjunctival goblet cells. Cont Lens Anterior Eye. 2016 Aug;39:266-269.
  13. Bullimore MA, Sinnott LT, Jones-Jordan LA. The risk of microbial keratitis with overnight corneal reshaping lenses. Optom Vis Sci. 2013 Sep;90:937-944.

(p. 44) Orthokeratology Today – Consider Ortho-k in Cases of Dry Eye
By Michael J. Lipson, OD

  1. Nichols JJ. Contact Lenses 2017. Contact Lens Spectrum. 2018 Jan;33:20-25, 42.
  2. García-Porta N, Rico-del-Viejo L, Martin-Gil A, Carracedo G, Pintor J, González-Méijome JM. Differences in Dry Eye Questionnaire Symptoms in Two Different Modalities of Contact Lens Wear: Silicone-Hydrogel in Daily Wear Basis and Overnight Orthokeratology. Biomed Res Int. 2016;2016:1242845
  3. Carracedo G, Martin-Gil A, Fonseca B and Pintor J. Effect Of Overnight Orthokeratology On Conjunctival Goblet Cells. Cont Lens Anterior Eye. 2016 Aug;39:266-269.

(p. 45) Treatment Plan – All Hands on Deck, the Dry Eye Tsunami Is Here
By Leo Semes, OD

  1. American Optometric Association. Care of the Patient with Ocular Surface Disorders. 1995 Mar 23, revised 2010. Available at https://www.aoa.org/documents/optometrists/CPG-10.pdf . Accessed on May 15, 2018.
  2. Albietz JM. Prevalence of Dry Eye Subtypes in Clinical Optometry Practice. Optom Vis Sci. 2000 Jul;77:357-363.
  3. Berehns A, Doyle JJ, Stern L, et al. Dysfunctional Tear Syndrome: a Delphi approach to treatment recommendations. Cornea. 2006 Sep;25:900-907.
  4. Lemp, MA, Baudouin C, Baum J, et al. The Definition and Classification of Dry Eye Disease: Report of the Definition and Classification Subcommittee of the International Dry Eye Work Shop (2007). Ocul Surf. 2007 Apr;5:75-92.
  5. Craig JP, Nelson JD, Azar DT, et al. TFOS DEWS II Report Executive Summary. Ocul Surf. 2017 Oct;15:802-812.
  6. Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II Epidemiology report. Ocul Surf. 2017 Jul;15:334-385.
  7. Farrand KF, Fridman M, Stillman IÖ, Schaumberg DA. Prevalence of diagnosed dry eye disease in the United States among adults aged 18 years and over. Am J Ophthalmol. 2017 Oct;182:90-99.
  8. Moon JH, Kim KW, Moon NJ. Smartphone use is a risk factor for pediatric dry eye disease according to region and age: a case control study. BMC Ophthalmol. 2016 Oct 28;16:188.
  9. Courtin R, Pereira B, Naughton G, et al. Prevalence of dry eye disease in visual display terminal workers: a systematic review and meta-analysis. BMJ Open. 2016 Jan 14;6:e009675.
  10. Wolffsohn JS, Arita R, Chalmers R. TFOS DEWS II Diagnostic Methodology report. Ocul Surf. 2017 Jul;15:539-574.
  11. Jones. L, Downie LE, Korb D, et al. TFOS DEWS II Management and therapy report. Ocul Surf. 2017 Jul;15:575-628.
  12. Waisbourd M, Pruzan NL, Johnson D, et al. The Philadelphia Glaucoma Detection and Treatment Project: Detection Rates and Initial Management. Ophthalmology. 2016 Aug;123:1667-1674.